These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11447908)

  • 1. [Pegylated interferons: preliminary review of their pharmacokinetic characteristics].
    Azanza Perea JR
    Rev Clin Esp; 2001 Apr; 201(4):205-12. PubMed ID: 11447908
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic modeling of pegylated-interferon alfa.
    Dimova RB; Talal AH
    J Hepatol; 2010 Sep; 53(3):418-20. PubMed ID: 20561707
    [No Abstract]   [Full Text] [Related]  

  • 3. [The interferons: pharmacology, mechanism of action, tolerance and side effects].
    Arnaud P
    Rev Med Interne; 2002 Nov; 23 Suppl 4():449s-458s. PubMed ID: 12481400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pegylated interferons: pharmacological basis].
    Macquin-Mavier I; Hezode C; Dhumeaux D
    Gastroenterol Clin Biol; 2002; 26(8-9):742-7. PubMed ID: 12434079
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics of pegylated interferons: what is misleading?
    Caliceti P
    Dig Liver Dis; 2004 Nov; 36 Suppl 3():S334-9. PubMed ID: 15645663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).
    Reddy KR
    Semin Liver Dis; 2004; 24 Suppl 2():33-8. PubMed ID: 15346244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
    García-García I; González-Delgado CA; Valenzuela-Silva CM; Díaz-Machado A; Cruz-Díaz M; Nodarse-Cuní H; Pérez-Pérez O; Bermúdez-Badell CH; Ferrero-Bibilonia J; Páez-Meireles R; Bello-Rivero I; Castro-Odio FR; López-Saura PA;
    BMC Pharmacol; 2010 Nov; 10():15. PubMed ID: 21092287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PEGylated recombinant human interferon-ω as a long-acting antiviral agent: structure, antiviral activity and pharmacokinetics.
    Yu W; Yu C; Wu L; Fang T; Qiu R; Zhang J; Yu T; Fu L; Chen W; Hu T
    Antiviral Res; 2014 Aug; 108():142-7. PubMed ID: 24936771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs.
    Cai Y; Zhang Z; Fan K; Zhang J; Shen W; Li M; Si D; Luo H; Zeng Y; Fu P; Liu C
    Regul Pept; 2012 Jan; 173(1-3):74-81. PubMed ID: 21985916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of hepatitis C treatment with pegylated interferons and ribavirin.
    Jiménez-Méndez R; Castañeda-Hernández G
    Ann Hepatol; 2010; 9 Suppl():61-4. PubMed ID: 20713998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated interferons.
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(2):87-99. PubMed ID: 12120178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New perspectives in the treatment of viral hepatitis C: pegylated interferon alpha].
    Alric L; Cacoub P
    Rev Med Interne; 2001 Oct; 22(10):922-5. PubMed ID: 11695314
    [No Abstract]   [Full Text] [Related]  

  • 13. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.
    Perry CM; Jarvis B
    Drugs; 2001; 61(15):2263-88. PubMed ID: 11772139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population PK-PD Model of Pegylated Interferon Alfa-2a in Healthy Korean Men.
    Jung YS; Chae D; Park K
    J Pharm Sci; 2018 Dec; 107(12):3171-3178. PubMed ID: 30179597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles.
    Bruno R; Sacchi P; Cima S; Maiocchi L; Novati S; Filice G; Fagiuoli S
    J Viral Hepat; 2012 Jan; 19 Suppl 1():33-6. PubMed ID: 22233411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated IFNs for chronic hepatitis C: an update.
    Grace MJ; Cutler DL; Bordens RW
    Expert Opin Drug Deliv; 2005 Mar; 2(2):219-26. PubMed ID: 16296749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects.
    Nieforth KA; Nadeau R; Patel IH; Mould D
    Clin Pharmacol Ther; 1996 Jun; 59(6):636-46. PubMed ID: 8681488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
    Jo YW; Youn YS; Lee SH; Kim BM; Kang SH; Yoo M; Choi EC; Lee KC
    Int J Pharm; 2006 Feb; 309(1-2):87-93. PubMed ID: 16406701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.
    Osinusi A; Bon D; Nelson A; Lee YJ; Poonia S; Shivakumar B; Cai SY; Wood B; Haagmans B; Lempicki R; Herrmann E; Sneller M; Polis M; Masur H; Kottilil S
    J Med Virol; 2014 Feb; 86(2):177-85. PubMed ID: 24166150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Successful therapy with pegylated interferon alfa-2a. Hepatitis C patients remain virus-free].
    MMW Fortschr Med; 2003 Sep; 145(35-36):56. PubMed ID: 14584218
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.